ID   BB65-RCC
AC   CVCL_1078
SY   BB65 RCC; BB65RCC; BB65; CAJE
DR   CLO; CLO_0009975
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1078
DR   Cell_Model_Passport; SIDM00191
DR   ChEMBL-Cells; CHEMBL3308283
DR   ChEMBL-Targets; CHEMBL2366247
DR   Cosmic; 753533
DR   Cosmic-CLP; 753533
DR   DepMap; ACH-002090
DR   EGA; EGAS00001000978
DR   GDSC; 753533
DR   GEO; GSM1669609
DR   IARC_TP53; 21188
DR   IARC_TP53; 26919
DR   LINCS_LDP; LCL-1763
DR   PharmacoDB; BB65RCC_76_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1078
DR   Wikidata; Q54795073
RX   PubMed=10074909;
RX   PubMed=14762065;
RX   PubMed=15585611;
RX   PubMed=18698046;
RX   PubMed=20164919;
RX   PubMed=22892449;
RX   PubMed=27397505;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   Population: Caucasian.
CC   HLA typing: A*02,26; B*44,49; C*07,16 (PubMed=15585611).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (Cosmic-CLP).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.53%; Native American=1.94%; East Asian, North=1.65%; East Asian, South=0%; South Asian=0.38%; European, North=59.69%; European, South=35.82% (PubMed=30894373).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 8
ST   D16S539: 12,13
ST   D5S818: 11,14
ST   D7S820: 11,12
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_6F66 ! BB65-EBV
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   PubMed=10074909; DOI=10.1002/(SICI)1097-0215(19990315)80:6<799::AID-IJC1>3.0.CO;2-U;
RA   Dumas F., Gala J.-L., Berteau P., Brasseur F., Eschwege P., Paradis V.,
RA   Lacour B., Philippe M., Loric S.;
RT   "Molecular expression of PSMA mRNA and protein in primary renal
RT   tumors.";
RL   Int. J. Cancer 80:799-803(1999).
//
RX   PubMed=14762065; DOI=10.1101/gr.2012304;
RA   Bignell G.R., Huang J., Greshock J., Watt S., Butler A.P., West S.,
RA   Grigorova M., Jones K.W., Wei W., Stratton M.R., Futreal P.A.,
RA   Weber B., Shapero M.H., Wooster R.;
RT   "High-resolution analysis of DNA copy number using oligonucleotide
RT   microarrays.";
RL   Genome Res. 14:287-295(2004).
//
RX   PubMed=15585611; DOI=10.1158/1078-0432.CCR-04-0072;
RA   Tykodi S.S., Warren E.H., Thompson J.A., Riddell S.R., Childs R.W.,
RA   Otterud B.E., Leppert M.F., Storb R., Sandmaier B.M.;
RT   "Allogeneic hematopoietic cell transplantation for metastatic renal
RT   cell carcinoma after nonmyeloablative conditioning: toxicity,
RT   clinical response, and immunological response to minor
RT   histocompatibility antigens.";
RL   Clin. Cancer Res. 10:7799-7811(2004).
//
RX   PubMed=18698046; DOI=10.1158/1078-0432.CCR-08-0028;
RA   Tykodi S.S., Fujii N., Vigneron N., Lu S.M., Mito J.K., Miranda M.X.,
RA   Chou J., Voong L.N., Thompson J.A., Sandmaier B.M., Cresswell P.,
RA   Van den Eynde B.J., Riddell S.R., Warren E.H.;
RT   "C19orf48 encodes a minor histocompatibility antigen recognized by
RT   CD8+ cytotoxic T cells from renal cell carcinoma patients.";
RL   Clin. Cancer Res. 14:5260-5269(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22892449; DOI=10.1097/CJI.0b013e318261d630;
RA   Tykodi S.S., Satoh S., Deming J.D., Chou J., Harrop R., Warren E.H.;
RT   "CD8+ T-cell clones specific for the 5T4 antigen target renal cell
RT   carcinoma tumor-initiating cells in a murine xenograft model.";
RL   J. Immunother. 35:523-533(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//